PT  - JOURNAL ARTICLE
AU  - Anoop S V Shah
AU  - Ciara Gribben
AU  - Jennifer Bishop
AU  - Peter Hanlon
AU  - David Caldwell
AU  - Rachael Wood
AU  - Martin Reid
AU  - Jim McMenamin
AU  - David Goldberg
AU  - Diane Stockton
AU  - Sharon Hutchinson
AU  - Chris Robertson
AU  - Paul M McKeigue
AU  - Helen M Colhoun
AU  - David A McAllister
TI  - Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households
AID  - 10.1101/2021.03.11.21253275
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.11.21253275
4099  - http://medrxiv.org/content/early/2021/03/21/2021.03.11.21253275.short
4100  - http://medrxiv.org/content/early/2021/03/21/2021.03.11.21253275.full
AB  - Background The effect of vaccination for COVID-19 on onward transmission is unknown.Methods A national record linkage study determined documented COVID-19 cases and hospitalisations in unvaccinated household members of vaccinated and unvaccinated healthcare workers from 8th December 2020 to 3rd March 2021. The primary endpoint was COVID-19 14 days following the first dose.Results The cohort comprised of 194,362 household members (mean age 31·1 ± 20·9 years) and 144,525 healthcare workers (mean age 44·4 ± 11·4 years). 113,253 (78·3%) of healthcare workers received at least one dose of the BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccine and 36,227 (25·1%) received a second dose. There were 3,123 and 4,343 documented COVID-19 cases and 175 and 177 COVID-19 hospitalisations in household members of healthcare workers and healthcare workers respectively. Household members of vaccinated healthcare workers had a lower risk of COVID-19 case compared to household members of unvaccinated healthcare worker (rate per 100 person-years 9·40 versus 5·93; HR 0·70, 95% confidence interval [CI] 0·63 to 0·78). The effect size for COVID-19 hospitalisation was similar, with the confidence interval crossing the null (HR 0·77 [95% CI 0·53 to 1·10]). The rate per 100 person years was lower in vaccinated compared to unvaccinated healthcare workers for documented (20·13 versus 8·51; HR 0·45 [95% CI 0·42 to 0·49]) and hospitalized COVID-19 (0·97 versus 0·14; HR 0·16 [95% CI 0·09 to 0·27]). Compared to the period before the first dose, the risk of documented COVID-19 case was lower at ≥ 14 days after the second dose for household members (HR 0·46 [95% CI 0·30to 0·70]) and healthcare workers (HR 0·08 [95% CI 0·04 to 0·17]).Interpretation Vaccination of health care workers was associated with a substantial reduction in COVID-19 cases in household contacts consistent with an effect of vaccination on transmission.Competing Interest StatementPM and HC have received research grants from AstraZeneca. There are no other competing interests.Clinical Protocols http://www.encepp.eu/encepp/viewResource.htm?id=39737 https://github.com/dmcalli2/hcw_vax Funding StatementASVS is funded via the British Heart Foundation through an intermediate clinical research fellowship (FS/19/17/34172), and DAM is funded via a Wellcome Trust intermediate clinical fellowship and Beit fellowship (201492/Z/16/Z). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the NHS Public Benefit and Privacy Panel (2021-0013) for use of the data and linkage.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis code will be made available here in an online repository on publication following peer review. Since our analysis involved data on unconsented participants, we are unable to share individual level data.